By FieldPulse Staff · March 22, 2026
Tags: eli-lilly, glp-1, diabetes, obesity, phase-3
Retatrutide, Lilly's triple GIP/GLP-1/glucagon receptor agonist, met its primary endpoint in the TRANSCEND-T2D-1 trial with A1C reductions of up to 2.0% and 16.8% body weight loss at 40 weeks — even as a new safety signal emerged that is still being characterized.
Eli Lilly announced positive Phase 3 results on March 19, 2026 for retatrutide in type 2 diabetes, the first of several pivotal readouts from its TRANSCEND clinical program. The data position retatrutide — a triple agonist hitting GIP, GLP-1, and glucagon receptors simultaneously — as a potential successor to tirzepatide (Mounjaro, Zepbound) with even greater metabolic impact. In the TRANSCEND-T2D-1 trial of more than 2,050 enrolled patients, retatrutide met its primary endpoint: A1C reductions of up to 2.0 percentage points at 40 weeks versus placebo in adults with T2D who had inadequate glyc